¼¼°èÀÇ Á¤¸Æ ³» ÀýÁ¦ ÀåÄ¡ ½ÃÀå
Endovenous Ablation Devices
»óǰÄÚµå : 1551621
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 192 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,039,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,117,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Á¤¸Æ ³» ÀýÁ¦ ÀåÄ¡ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 6¾ï 9,360¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸Á

2023³â 5¾ï 2,060¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Á¤¸Æ ³» ÀýÁ¦ ÀåÄ¡ ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 6¾ï 9,360¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2023-2030³â µ¿¾È 4.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Á¤¸Æ ³» ·¹ÀÌÀú ÀýÁ¦¼ú(EVLT) ÀåÄ¡´Â 4.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÏ¿© ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 4¾ï 8,600¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. RFA(Radiofrequency Ablation Therapy) ±â±â ºÎ¹®Àº ºÐ¼® ±â°£ µ¿¾È 4.0%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀå 1¾ï 4,180¸¸ ´Þ·¯, Áß±¹Àº CAGR 7.9%·Î ¼ºÀå Àü¸Á

¹Ì±¹ÀÇ Á¤¸Æ ÀýÁ¦ ÀåÄ¡ ½ÃÀåÀº 2023³â 1¾ï 4,180¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2023-2030³â 7.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2030³â±îÁö 1¾ï 4,880¸¸ ´Þ·¯ ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ºÐ¼® ±â°£ µ¿¾È °¢°¢ 1.4%¿Í 3.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ 2.3%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è Á¤¸Æ ÀýÁ¦¼ú ±â±â ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

Á¤¸Æ ³» ÀýÁ¦ ÀåÄ¡´Â ÇÏÁöÁ¤¸Æ·ù Ä¡·á¸¦ ¾î¶»°Ô º¯È­½Ãų ¼ö ÀÖÀ»±î?

Á¤¸Æ ³» ÀýÁ¦ ÀåÄ¡´Â Á¤¸Æ·ù Ä¡·á¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, Á¤¸Æ ¹Ú¸®¼ú°ú °°Àº ÀüÅëÀûÀÎ ¼ö¼úÀû ¹æ¹ý¿¡ ´ëÇÑ ÃÖ¼Ò Ä§½ÀÀû Ä¡·á¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÇÏÁöÁ¤¸Æ·ù´Â Á¾Á¾ ´Ù¸®¿¡ ³ªÅ¸³ª´Â ºÎÇ®¾î ¿À¸£°í µÚƲ¸° Á¤¸ÆÀÌ Æ¯Â¡À̸ç, Ç÷¾×ÀÌ °íÀÌ´Â Á¤¸Æ ³» °áÇÔ ÀÖ´Â ÆÇ¸·À¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÀÌ »óŸ¦ ¹æÄ¡ÇÏ¸é ºÒÆíÇÔ°ú ÅëÁõ, ±×¸®°í ´õ ½É°¢ÇÑ ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¤¸Æ ³» ¼ÒÀÛ¼úÀº ¿­ ¿¡³ÊÁö ¶Ç´Â È­ÇÐ ¿¡³ÊÁö¸¦ Á÷Á¢ Á¤¸Æ¿¡ Á¶»çÇÏ¿© Á¤¸ÆÀ» ºØ±«½ÃŰ°í Æó¼â½ÃŰ´Â ¹æ¹ýÀÔ´Ï´Ù. ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Ä¡·áµÈ Á¤¸ÆÀº ü³»¿¡ Èí¼öµÇ°í Ç÷·ù´Â ÀÚ¿¬½º·´°Ô °Ç°­ÇÑ Á¤¸ÆÀ¸·Î ¹æÇâÀ» ÀüȯÇÕ´Ï´Ù. ÀÌ ¼ö¼úÀº ÀϹÝÀûÀ¸·Î ±¹¼Ò ¸¶Ãë·Î ½ÃÇàµÇ¸ç, ±âÁ¸ ¼ö¼ú¿¡ ºñÇØ ȸº¹ ½Ã°£ ´ÜÃà, ÅëÁõ °¨¼Ò, ÈäÅÍ °¨¼Ò µî ¿©·¯ °¡Áö ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. Á¤¸Æ ³» ¼ÒÀÛ¼úÀº Á¤¸Æ·ùÀÇ Àå±âÀûÀÎ °³¼± È¿°ú¸¦ ¹Ý¿µÇÏ¿© ȯÀÚ¿Í ÀÇ·áÁø ¸ðµÎ¿¡°Ô ÁöÁö¸¦ ¹Þ°í ÀÖÀ¸¸ç, Àü ¼¼°è ¸¹Àº Áö¿ª¿¡¼­ Ç¥ÁØ Ä¡·á¹ýÀ¸·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù.

Á¤¸Æ ³» ÀýÁ¦¼ú Àåºñ´Â ¾î¶² ±â¼ú Çõ½ÅÀ¸·Î °³¼±µÇ°í Àִ°¡?

±â¼ú Çõ½ÅÀº Á¤¸Æ ³» ÀýÁ¦ ÀåºñÀÇ ¾ÈÀü¼º, È¿°ú ¹× Á¤È®¼ºÀ» Áö¼ÓÀûÀ¸·Î °³¼±ÇÏ¿© Àû¿ë ¹üÀ§¸¦ ³ÐÈ÷°í ȯÀÚ °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. RFA(Radiofrequency Ablation Therapy, RFA)¿Í EVLT(Endovenous Laser Therapy, EVLT)´Â ÀÌ·¯ÇÑ Àåºñ¿¡ »ç¿ëµÇ´Â µÎ °¡Áö ÁÖ¿ä ±â¼ú·Î, °¢°¢ °íÀ¯ÇÑ ÀåÁ¡À» °¡Áö°í ÀÖ½À´Ï´Ù. È¿°ú¸¦ ¾ò´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ÃÖ±Ù µ¿Çâ¿¡´Â º¸´Ù ÀÛ°í »ç¿ëÇϱ⠽¬¿ì¸ç Á¦¾î ±â´ÉÀÌ °­È­µÈ ÀåºñÀÇ °³¹ßÀÌ Æ÷ÇÔµÇ¾î ½Ã¼ú Áß ´õ ³ôÀº Á¤È®µµ¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, RFAÀÇ °æ¿ì Ŭ·ÎÀú ÆÐ½ºÆ® Ä«Å×ÅÍ, EVLTÀÇ °æ¿ì ¹æ»çÇü ¼¶À¯ Ä«Å×ÅÍ¿Í °°Àº Ä«Å×ÅÍ ¼³°èÀÇ Çõ½ÅÀº Á¤¸Æ ³» ¿¡³ÊÁö ºÐÆ÷¸¦ °³¼±ÇÏ¿© º¸´Ù ¾ÈÁ¤ÀûÀÎ °á°ú¿Í ÇÕº´Áõ À§Çè °¨¼Ò·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ ¹ßÀüÀº ¿­À̳ª ´Ù·®ÀÇ ¸¶ÃëÁ¦°¡ ÇÊ¿ä ¾ø´Â ºñ¿­ ¹× ºñºÐ»ç ¹æ½ÄÀÇ ÀýÁ¦¹ý(MOCA)À̳ª ½Ã¾Æ³ë¾ÆÅ©¸±·¹ÀÌÆ® Á¢ÂøÁ¦¸¦ ÀÌ¿ëÇÑ Æó»ö°ú °°Àº ºñ¿­ ¹× ºñºÐ»ç ¹æ½ÄÀÇ µîÀåÀ¸·Î ȯÀÚÀÇ ºÒÆíÇÔ°ú ȸº¹ ½Ã°£À» ´õ¿í ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ¹ßÀüÀ¸·Î Á¤¸Æ ³» ¼ÒÀÛ¼úÀº ´õ¿í Ä£¼÷Çϰí È¿°úÀûÀÎ Ä¡·á¹ýÀÌ µÇ¾î ´õ ¸¹Àº ȯÀÚµéÀÇ ¿ä±¸¿¡ ºÎÀÀÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

ȯÀÚÀÇ ¼±È£µµ ¹× °Ç°­ °ü¸® µ¿ÇâÀº Á¤¸Æ ÀýÁ¦ ÀåÄ¡ »ç¿ë¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÃÆ´Â°¡?

ȯÀÚÀÇ ¼±È£µµ¿Í °Ç°­ °ü¸® Æ®·»µå´Â Á¤¸Æ ³» ÀýÁ¦ ÀåÄ¡ äÅÿ¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ȯÀÚµéÀÌ ´ú ħ½ÀÀûÀÌ°í ´Ù¿îŸÀÓÀÌ ÀûÀº Ä¡·á¸¦ ¿øÇϸ鼭 Á¤¸Æ ³» ¼ÒÀÛ¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ¿Ü·¡ ¼ö¼ú Áõ°¡¿Í ÃÖ¼Ò ºñ¿ëÀ¸·Î ÃÖ»óÀÇ °á°ú¸¦ ¾ò´Â µ¥ ÁßÁ¡À» µÐ °¡Ä¡ ±â¹Ý Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁø °Íµµ ÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Á¤¸Æ ³» ¼ÒÀÛ¼úÀÇ ÆíÀǼºÀº ÀÌ·¯ÇÑ Ãß¼¼¿Í Àß ¸Â¾Æ¶³¾îÁö´Âµ¥, ȯÀÚ°¡ ÇÏ·ç ¸¸¿¡ ÀÏ»ó »ýȰ·Î º¹±ÍÇÒ ¼ö ÀÖ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¶ÇÇÑ, Å« ÈäÅͰ¡ ³²Áö ¾Ê°í Àç¹ß À§ÇèÀÌ ³·´Ù´Â ÀåÁ¡À¸·Î ÀÎÇØ ¹Ì¿ëÀûÀÎ Ãø¸éÀ» Áß½ÃÇϴ ȯÀڵ鿡°Ôµµ Àαâ ÀÖ´Â Ä¡·á¹ýÀÔ´Ï´Ù. ¸¸¼ºÀûÀÎ Á¤¸ÆÁúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡´Â Á¤¸Æ ³» ¼ÒÀÛ¼ú°ú °°Àº È¿°úÀûÀÌ°í Æí¸®ÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀÌ È¯ÀÚ Áß½ÉÀÇ Ä¡·á¸¦ Á¡Á¡ ´õ ¿ì¼±½ÃÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ÀåºñÀÇ Àαâ¿Í »ç¿ëÀº °è¼Ó Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¤¸Æ ÀýÁ¦ ÀåÄ¡ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

Á¤¸Æ ÀýÁ¦ ÀåÄ¡ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ȯÀÚÃþÀÇ º¯È­, ÀÇ·á °üÇàÀÇ ÁøÈ­¿Í ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ´Â ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ °í·ÉÈ­, ºñ¸¸, Àå½Ã°£ ¼­¼­ ÀÏÇÏ´Â µî À§Çè ¿äÀÎÀ» °¡Áø »ç¶÷µé »çÀÌ¿¡¼­ Á¤¸Æ·ù À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. º¸´Ù È¿À²ÀûÀÌ°í ¾ÈÀüÇÑ ÀýÁ¦ ÀåºñÀÇ °³¹ß°ú °°Àº ±â¼úÀû ¹ßÀüÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ Ä¡·áÀÇ ¹üÀ§°¡ È®´ëµÇ¾î ´õ ¸¹Àº ȯÀÚ±ºÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, Àúħ½ÀÀû Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Á¶±â ȸº¹°ú ¹Ì¿ëÀû °á°úÀÇ °³¼±¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁø °Íµµ Å« ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿Ü·¡ Áø·á·ÎÀÇ Àüȯ°ú ºñ¿ë È¿À²¼º°ú ȯÀÚ ¸¸Á·µµ¸¦ Áß½ÃÇÏ´Â °¡Ä¡ ±â¹Ý ÀÇ·á ¸ðµ¨ Ã¤ÅÃÀÌ Áõ°¡Çϸ鼭 Á¤¸Æ ³» ÀýÁ¦¼ú Àåºñ¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ ÀÇ·á ÀÎÇÁ¶ó°¡ Àü ¼¼°èÀûÀ¸·Î È®´ëµÇ¸é¼­ ÷´Ü ÀÇ·á ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ¾î ½ÃÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº Àåºñ ±â¼ú ¹× ½Ã¼úÀÇ Áö¼ÓÀûÀÎ Çõ½Å°ú ÇÔ²² Á¤¸Æ ÀýÁ¦¼ú ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÃÑ 51°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Endovenous Ablation Devices Market to Reach US$693.6 Million by 2030

The global market for Endovenous Ablation Devices estimated at US$520.6 Million in the year 2023, is expected to reach US$693.6 Million by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Endovenous Laser Ablation Therapy (EVLT) Devices, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$486.0 Million by the end of the analysis period. Growth in the Radiofrequency Ablation (RFA) Devices segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$141.8 Million While China is Forecast to Grow at 7.9% CAGR

The Endovenous Ablation Devices market in the U.S. is estimated at US$141.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$148.8 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Endovenous Ablation Devices Market - Key Trends and Drivers Summarized

How Do Endovenous Ablation Devices Transform the Treatment of Varicose Veins?

Endovenous ablation devices have revolutionized the treatment of varicose veins, offering a minimally invasive alternative to traditional surgical methods like vein stripping. Varicose veins, characterized by swollen, twisted veins that often appear on the legs, result from faulty valves within the veins that cause blood to pool. This condition can lead to discomfort, pain, and more severe complications if left untreated. Endovenous ablation works by delivering thermal or chemical energy directly into the affected vein, causing it to collapse and seal shut. Over time, the treated vein is absorbed by the body, and blood flow is naturally redirected to healthier veins. This procedure, typically performed under local anesthesia, offers numerous advantages, including shorter recovery times, reduced pain, and minimal scarring compared to traditional surgery. The growing preference for endovenous ablation among both patients and healthcare providers reflects its effectiveness in providing long-term relief from varicose veins, making it the standard of care in many parts of the world.

What Technological Innovations Are Enhancing Endovenous Ablation Devices?

Technological innovations are continually enhancing the safety, efficacy, and precision of endovenous ablation devices, broadening their application and improving patient outcomes. Radiofrequency ablation (RFA) and endovenous laser therapy (EVLT) are the two primary technologies used in these devices, each offering unique benefits. RFA uses radiofrequency energy to heat the vein wall, causing it to collapse, while EVLT employs laser energy to achieve the same result. Recent advancements in these technologies include the development of more compact, user-friendly devices with enhanced control features, allowing for greater precision during the procedure. Furthermore, innovations in catheter design, such as the introduction of closure fast catheters in RFA and radial fiber catheters in EVLT, have improved energy distribution within the vein, leading to more consistent results and reduced risk of complications. Another significant development is the advent of non-thermal, non-tumescent ablation methods, such as mechanochemical ablation (MOCA) and cyanoacrylate glue occlusion, which eliminate the need for heat and large volumes of anesthetic, further minimizing patient discomfort and recovery time. These technological advancements are making endovenous ablation procedures more accessible and effective, catering to a broader range of patient needs.

How Are Patient Preferences and Healthcare Trends Influencing the Use of Endovenous Ablation Devices?

Patient preferences and broader healthcare trends are playing a crucial role in shaping the adoption of endovenous ablation devices. As patients increasingly seek treatments that are less invasive and require minimal downtime, the demand for endovenous ablation has surged. This shift is partly driven by the rise in outpatient procedures and the growing emphasis on value-based care, where the focus is on achieving the best possible outcomes at the lowest cost. The convenience of endovenous ablation, which often allows patients to return to normal activities within a day, aligns well with these trends. Additionally, the aesthetic benefits of the procedure, including the absence of large scars and the reduced risk of recurrence, have made it a popular choice among individuals concerned about the cosmetic aspects of varicose veins. The expanding demographic of aging populations, who are more prone to chronic venous insufficiency, further drives the demand for effective and convenient treatments like endovenous ablation. As healthcare providers increasingly prioritize patient-centered care, the popularity and utilization of these devices are expected to continue growing.

What Is Driving Growth in the Endovenous Ablation Devices Market?

The growth in the endovenous ablation devices market is driven by several factors closely linked to technological advancements, changing patient demographics, and evolving healthcare practices. The increasing prevalence of varicose veins, particularly among the aging population and individuals with risk factors such as obesity and prolonged standing, has led to a greater need for effective treatment options. Technological advancements, such as the development of more efficient and safer ablation devices, have expanded the scope of these treatments, making them accessible to a broader patient base. The rising awareness of minimally invasive treatment options and the associated benefits of quicker recovery and improved cosmetic outcomes are also significant drivers. Additionally, the shift towards outpatient procedures and the increasing adoption of value-based healthcare models, which emphasize cost-effectiveness and patient satisfaction, have boosted the demand for endovenous ablation devices. The global expansion of healthcare infrastructure, particularly in emerging markets, is further propelling the market as access to advanced medical technologies improves. These factors, combined with ongoing innovations in device technology and procedural techniques, are fueling the continued growth of the endovenous ablation devices market.

Select Competitors (Total 51 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â